Monoclonal Antibodies

Monoclonal Antibodies

Antibody Cocktail drug

• Imdevimab and Casirivimab and bind simultaneously to different, non-overlapping epitopes on the SARS-CoV-2 spike (S) glycoprotein. The simultaneous binding prevents its attachment to the ACE-2 receptors, thereby blocking viral entry into the cells.
• It was observed that A single IV infusion of the combined regimen (1.2g of Casirivamab and Imdevimab) could reduce the risk of hospitalization or death by 70 per cent.
• The use of these monoclonal antibodies in the right patients at the right time may benefit individuals by halting progression to severe disease.

Who will benefit from the COVID-19 antibody-drug cocktail?

• Casirivimab and Imdevimab should be used in patients who are hospitalized due to COVID-19, chronic lung disease including asthma, cardiovascular disease including hypertension, obesity, and diabetes mellitus etc.

When should the antibody-drug cocktail treatment be used?

Image courtesy: Economic Times

• For those who are at risk of progression to severe disease, it reduces the risk of hospitalization and mortality.
• It is important that it should be given in the early symptomatic phase within 10 days of the onset of symptoms.  

More from us 

Free Study Notes / Material

Current Affairs for MPSC Exams PDF

NCERT Summary PDF (Hindi/ English)

Get Unlimited access to Structured Live Courses and Mock Tests- Online Classroom Program

Get Unlimited access to 40+ Mock Tests-BYJU'S Exam Prep Test Series

Daily, Monthly, Yearly Current Affairs Digest, Daily Editorial Analysis, Free PDF's & more, Join our Telegram Group Join Now